Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1949 1
1954 1
1955 1
1956 4
1957 9
1958 10
1959 11
1960 18
1961 23
1962 38
1963 72
1964 100
1965 86
1966 86
1967 112
1968 196
1969 124
1970 124
1971 178
1972 164
1973 174
1974 165
1975 155
1976 155
1977 155
1978 162
1979 154
1980 150
1981 128
1982 131
1983 118
1984 125
1985 131
1986 134
1987 180
1988 219
1989 441
1990 550
1991 673
1992 679
1993 653
1994 718
1995 649
1996 642
1997 570
1998 606
1999 533
2000 549
2001 583
2002 701
2003 681
2004 789
2005 917
2006 906
2007 1052
2008 1001
2009 835
2010 881
2011 813
2012 765
2013 797
2014 647
2015 531
2016 516
2017 455
2018 390
2019 186
2020 5
Text availability
Article attribute
Article type
Publication date

Search Results

23,223 results
Results by year
Filters applied: . Clear all
Page 1
Physiology and pathophysiology of renal erythropoietin-producing cells.
Shih HM, et al. J Formos Med Assoc 2018 - Review. PMID 29655605 Free article.
Whereas there has been a significant improvement of understanding the underlying mechanism of erythropoiesis, the treatment of renal anemia is still restricted to erythropoietin (EPO)-stimulating agents. The purpose of this article is to review the physiology of erythropoiesis, functional role of EPO and underlying molecular and cellular basis that regulate EPO production. ...
Whereas there has been a significant improvement of understanding the underlying mechanism of erythropoiesis, the treatment of renal …
Non-hematogenic activity of erythropoietin.
Stárka L and Dušková M. Vnitr Lek 2019 - Review. PMID 31487995
Erythropoietin reduces hyperglycaemia and retards proliferative retinopathy in diabetic patients. Consequently, erythropoietin may be of therapeutic value for a variety of disorders. This short review provides an insight into the nonhemopoietic role of erythropoietin and its mechanisms of action. For elimination of polycythaemia after erythropoietin administration analogues without haematopoietic activity were prepared and tested in animals and in some cases also evaluated in clinical trials....
Erythropoietin reduces hyperglycaemia and retards proliferative retinopathy in diabetic patients. Consequently, erythropoietin
Roxadustat: First Global Approval
Dhillon S. Drugs 2019 - Review. PMID 30805897
Inhibition of these enzymes reduces HIF breakdown and promotes HIF activity, leading to an increase in endogenous erythropoietin production, thereby enhancing erythropoiesis. ...HIF regulates the expression of genes in response to reduced oxygen levels, including genes required for erythropoiesis and iron metabolism. ...
Inhibition of these enzymes reduces HIF breakdown and promotes HIF activity, leading to an increase in endogenous erythropoietin prod …
Renal association clinical practice guideline on Anaemia of Chronic Kidney Disease
Mikhail A, et al. BMC Nephrol 2017 - Review. PMID 29191165 Free PMC article.
Chronic kidney disease patients may not be able to utilise their own body's iron stores effectively and hence, many patients, particularly those receiving haemodialysis, may require additional iron treatment, usually provided by infusion.With further weakening of kidney function, patients with chronic kidney disease may need additional treatment with a substance called erythropoietin which drives the bone marrow to produce its own blood. ...Any patients will eventually require treatment with erythropoietin or similar products that are given by injection.Over the last few years, several iron and erythropoietin products have been licensed for treating anaemia in chronic kidney disease patients. ...
Chronic kidney disease patients may not be able to utilise their own body's iron stores effectively and hence, many patients, particularly t …
Erythropoietin: A potential drug in the management of diabetic neuropathy.
Suarez-Mendez S, et al. Biomed Pharmacother 2018 - Review. PMID 30021390
Erythropoietin (EPO) is required for promoting the progress of erythroid differentiation. However, the discovery of EPO and the EPO receptor (EPOR) in the nervous system may contribute to new treatment strategies for the use of EPO in neurodegenerative disorders. ...
Erythropoietin (EPO) is required for promoting the progress of erythroid differentiation. However, the discovery of EPO and the EPO r
Source and microenvironmental regulation of erythropoietin in the kidney.
Nolan KA and Wenger RH. Curr Opin Nephrol Hypertens 2018 - Review. PMID 29746306
PURPOSE OF REVIEW: Historically, the identity of O2-sensing renal erythropoietin (Epo)-producing (REP) cells was a matter of debate. ...
PURPOSE OF REVIEW: Historically, the identity of O2-sensing renal erythropoietin (Epo)-producing (REP) cells was a matter of debate. …
Erythropoietin induces bone marrow and plasma fibroblast growth factor 23 during acute kidney injury.
Toro L, et al. Kidney Int 2018. PMID 29395333
Erythropoietin, a kidney-derived hormone that targets erythropoietic cells, increases in AKI. Here we tested whether an acute increase of plasma erythropoietin induces FGF23 expression in erythropoietic cells of bone marrow thereby contributing to the increase of circulating FGF23 in AKI. ...Erythropoietin increased FGF23 expression in vivo and in bone marrow cell cultures via the homodimeric erythropoietin receptor. ...
Erythropoietin, a kidney-derived hormone that targets erythropoietic cells, increases in AKI. Here we tested whether an acute
Serum erythropoietin levels, breast cancer and breast cancer-initiating cells.
Bhat K, et al. Breast Cancer Res 2019. PMID 30700319 Free PMC article.
The use of erythropoiesis-stimulating agents has come under scrutiny after prospective clinical trials using recombinant erythropoietin to correct anemia reported increased incidence of thromboembolic events and cancer-related deaths. ...CONCLUSIONS: We conclude that physiologically slow-rising serum erythropoietin levels in response to tumor-related or chemotherapy-induced anemia, as opposed to large doses of recombinant erythropoietin, do not increase the pool of breast cancer-initiating cells....
The use of erythropoiesis-stimulating agents has come under scrutiny after prospective clinical trials using recombinant erythropo
Erythropoietin in Critical Illness and Trauma.
French C. Crit Care Clin 2019 - Review. PMID 30784609
Erythropoietin (EPO) is a 34kD pleiotropic cytokine that was first identified as being essential for red blood cell (RBC) production. ...
Erythropoietin (EPO) is a 34kD pleiotropic cytokine that was first identified as being essential for red blood cell (RBC) production.
23,223 results
Jump to page
Feedback